Organon & Co - Company Profile
Powered by 
All the sales intelligence you need on Organon & Co in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Organon & Co fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Organon & Co.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Organon & Co (Organon) is a healthcare company. The company discovers and develops biosimilars and medicines. It provides medicines and solutions for various conditions including respiratory, cardiovascular, dermatology, non-opioid pain, women’s health and others. The company’s products include mometasone furoate inhalation powder, follitropin beta injection, alendronate sodium medicine and others. Organon distributes and sells its products through various channels including hospitals, government agencies, drug wholesalers and retailers and managed healthcare providers. It collaborates with pharmaceutical and biopharmaceutical businesses to market its products. The company operates manufacturing facilities in Belgium, Mexico, the Netherlands, Brazil, Indonesia, and the UK. Organon is headquartered in Jersey City, New Jersey, the US.
Headquarters
United States of America
Address
30 Hudson Street, Fl 33, Jersey City, New Jersey, 07302
Website
www.organon.com
Telephone
1 551 4306900
No of Employees
10,000
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
OGN (NYSE)
Revenue (2024)
$6.2B
-2.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-78.4%
(2024 vs 2023)
Market Cap*
$3.6B
Net Profit Margin (2024)
XYZ
-77.7%
(2024 vs 2023)
* As of and is in US$
Organon & Co premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | Asmanex |
| Biosimilars | Asmanex Twisthaler |
| Women's Health Product | Celestone Soluspan |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In June, the company received approval from the US Food and Drug Administration for TOFIDENCE (tocilizumab-bavi) injection, for intravenous use, a biosimilar to ACTEMRA (tocilizumab). |
| 2026 | Contracts/Agreements | In May, the company entered into a supply agreement with Hanmi Pharmaceutical to transport three combination medicines for the Malaysian and Philippine markets. |
| 2026 | Contracts/Agreements | In June, the company expanded its agreement with Samsung Bioepis to obtain commercialization rights in Canada for PYZCHIVA, Samsung Bioepis’s biosimilar referencing STELARA (ustekinumab). |
Competitor Comparison
| Key Parameters | Organon & Co | Catalent Inc | Charles River Laboratories International Inc | Genmab AS | Qiagen NV |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Denmark | Netherlands |
| City | Jersey City | Somerset | Wilmington | Valby | Venlo |
| State/Province | New Jersey | New Jersey | Massachusetts | - | - |
| No. of Employees | 10,000 | 16,900 | 18,300 | 2,682 | 5,654 |
| Entity Type | Public | Private | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Carrie S. Cox | Chairman | Executive Board | 2021 | 68 |
| Matthew Walsh | Executive Vice President; Chief Financial Officer | Senior Management | 2021 | 59 |
| Daniel Karp | Chief Strategy Officer; Head - Corporate Development | Senior Management | 2024 | 48 |
| Juan Camilo Arjona Ferreira | Head - Research & Development; Chief Medical Officer; Executive Vice President | Senior Management | 2024 | 56 |
| Rachel Stahler | Chief Digital and Growth Officer; Executive Vice President | Senior Management | 2025 | 50 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer